PuSH - Publikationsserver des Helmholtz Zentrums München

Export: TXT Text RIS Endnote (RIS) BIB BibTeX
Steenblock, C.* ; Schwarz, P.E. ; Ludwig, B. ; Linkermann, A.* ; Zimmet, P.* ; Kulebyakin, K.* ; Tkachuk, V.A.* ; Markov, A.G.* ; Lehnert, H.* ; Hrabě de Angelis, M. ; Rietzsch, H.* ; Rodionov, R.N.* ; Khunti, K.* ; Hopkins, D.* ; Birkenfeld, A.L. ; Boehm, B.* ; Holt, R.I.G.* ; Skyler, J.S.* ; deVries, J.H.* ; Renard, E.* ; Eckel, R.H.* ; Alberti, K.G.M.M.* ; Geloneze, B.* ; Chan, J.C.* ; Mbanya, J.C.* ; Onyegbutulem, H.C.* ; Ramachandran, A.* ; Basit, A.* ; Hassanein, M.T.* ; Bewick, G.A.* ; Spinas, G.A.* ; Beuschlein, F.* ; Landgraf, R.* ; Rubino, F.* ; Mingrone, G.* ; Bornstein, S.R.

COVID-19 and metabolic disease: Mechanisms and clinical management.

Lancet Diabet. Endocrinol. 9, 786-798 (2021)
Postprint DOI PMC
Open Access Green
Up to 50% of the people who have died from COVID-19 had metabolic and vascular disorders. Notably, there are many direct links between COVID-19 and the metabolic and endocrine systems. Thus, not only are patients with metabolic dysfunction (eg, obesity, hypertension, non-alcoholic fatty liver disease, and diabetes) at an increased risk of developing severe COVID-19 but also infection with SARS-CoV-2 might lead to new-onset diabetes or aggravation of pre-existing metabolic disorders. In this Review, we provide an update on the mechanisms of how metabolic and endocrine disorders might predispose patients to develop severe COVID-19. Additionally, we update the practical recommendations and management of patients with COVID-19 and post-pandemic. Furthermore, we summarise new treatment options for patients with both COVID-19 and diabetes, and highlight current challenges in clinical management.
Impact Factor
Scopus SNIP
Web of Science
Times Cited
Scopus
Cited By
Altmetric
32.069
8.020
5
24
Tags
Anmerkungen
Besondere Publikation
Auf Hompepage verbergern

Zusatzinfos bearbeiten
Eigene Tags bearbeiten
Privat
Eigene Anmerkung bearbeiten
Privat
Auf Publikationslisten für
Homepage nicht anzeigen
Als besondere Publikation
markieren
Publikationstyp Artikel: Journalartikel
Dokumenttyp Review
Schlagwörter Insulin-resistance; Risk-factors; Inflammation; Association; Outcomes; Obesity; Ace2; Mortality; People; Prevention
Sprache englisch
Veröffentlichungsjahr 2021
HGF-Berichtsjahr 2021
ISSN (print) / ISBN 2213-8587
e-ISSN 2213-8595
Zeitschrift Lancet Diabetes and Endocrinology
Quellenangaben Band: 9, Heft: 11, Seiten: 786-798 Artikelnummer: , Supplement: ,
Verlag Elsevier
Verlagsort Ste 800, 230 Park Ave, New York, Ny 10169 Usa
Begutachtungsstatus Peer reviewed
Institut(e) Institute of Pancreatic Islet Research (IPI)
Institute of Experimental Genetics (IEG)
Institute of Diabetes Research and Metabolic Diseases (IDM)
POF Topic(s) 90000 - German Center for Diabetes Research
30201 - Metabolic Health
Forschungsfeld(er) Helmholtz Diabetes Center
Genetics and Epidemiology
PSP-Element(e) G-502600-007
G-502600-004
G-500600-001
G-502400-001
G-502600-001
Förderungen DFG
Deutsche Forschungsgemeinschaft, a German Research foundation
DOI 10.1016/S2213-8587(21)00244-8
WOS ID WOS:000731732800011
Scopus ID 85117325389
PubMed ID 34619105
Erfassungsdatum 2021-10-27
[➜Korrektur melden]